
SRRK Stock Forecast & Price Target
SRRK Analyst Ratings
Bulls say
Scholar Rock Holding Corp has shown positive market momentum, with shares increasing approximately 4% following recent news. The company's management successfully addressed production observations at a contract development and manufacturing organization (CDMO) facility, enhancing confidence in their operational capabilities. Furthermore, despite encountering a complete response letter (CRL), there remains strong long-term conviction in apitegromab's potential as a multi-blockbuster therapy due to its robust clinical profile in addressing a significant unmet medical need.
Bears say
Scholar Rock Holding Corp faces significant challenges as the commercial launch of its lead candidate, apitegromab, has been postponed from Q4 2025 to Q2 2026 for the US market and from Q2 2026 to Q3 2026 for the EU market due to regulatory delays. The issuance of a Complete Response Letter (CRL) necessitates a resubmission of the Biologics License Application (BLA) to the FDA, indicating a setback for the company that could adversely affect anticipated revenue timelines. This delay contributes to a recalibration of financial models, resulting in a slight decrease in projections, which casts uncertainty over the company's near-term financial outlook amidst its operational challenges.
This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.
SRRK Analyst Forecast & Price Prediction
Start investing in SRRK
Order type
Buy in
Order amount
Est. shares
0 shares